Operator fluency on fresh ground

Ascendis Pharma A/S (ASND) — this company's answers

The model's full reasoning — Q1 2018 call → NOWe need to answer YES or NO based on the transcript. The question asks: "On this call, when analysts probe a RECENTLY EMERGED positive element of the business — something whose meaningful contribution began only within roughly the last few quarters — does management respond with UNHESITATING, GRANULAR OPERATIONAL COMMAND: answering follow-up questions about that new element with specific, present-tense working detail ... while conveying that the element's contribution to the reported results is still early?" We need to identify if there is such an element probed by analysts. The analysts' questions: There are two questions from Joseph Schwartz and one from an unidentified analyst. The first question from Hugo (unidentified) asks about TransCon CNP: "do you think we could get insight into whether TransCon CNP would have lower rates of hypotension with the top-line data in 4Q?" And then also about expanding into new therapeutic verticals. Jonathan Leff answers: "Yes. I think we can very clearly establish the lack of hypotension in the Phase 1 volunteer study. We will push to relatively high doses. Notably, we've been unable to cause hypotension in our preclinical models and we fully expect that we will reproduce that finding in the Phase 1 study. So we should pretty clearly be able to demonstrate that. As far as other therapeutic indications, hypochondroplasia comes to mind but there's a whole host of other FGFR3 and R2 related disorders any one of which would lend themselves to a once-weekly therapy over a daily therapy, so scientifically there's a lot of rationale for multiple diseases." That is about TransCon CNP, which is a recently emerged element? The call mentions that TransCon CNP recently began dosing subjects. It's a Phase 1 trial. So it's young. But the analyst's question is about whether the data will show lower rates of hypotension. Management answers with a prediction, not present-tense operational detail. They say "we will push to relatively high doses" and "we've been unable to cause hypotension in our preclinical models" - that's not granular operational detail about how it's being produced, delivered, staffed, scheduled, priced, or scaled. It's more about expectations. Also the second part about therapeutic verticals is general. The second question from Joseph Schwartz asks about takeaways from the Adcom on achondroplasia.

← Back to the full ASND analysis